Skip to main content

RIGL

Stock
Health Care
Biotechnology

Performance overview

RIGL Price
Price Chart

Forward-looking statistics

Beta
1.68
Risk
86.72%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.

Company info

SectorHealth Care
IndustryBiotechnology
Employees213
Market cap$166.6M

Fundamentals

Enterprise value$358.7M
Revenue$203.1M
Revenue per employee—
Profit margin18.31%
Debt to equity544.23

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$2.09
Dividend per share—
Revenue per share$11.51
Avg trading volume (30 day)$4M
Avg trading volume (10 day)$5M
Put-call ratio—

Macro factor sensitivity

Growth-0.7
Credit+9.7
Liquidity+3.0
Inflation-6.1
Commodities-2.5
Interest Rates-0.7

Valuation

Dividend yield0.00%
PEG Ratio21.51
Price to sales1.67
P/E Ratio21.51
Enterprise Value to Revenue1.77
Price to book18.22

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend day—

News

Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research (May 29, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free